• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Are Venus Concept Shares Moving

    6/7/24 3:23:11 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email

    Venus Concept Inc. (NASDAQ:VERO) shares are experiencing a surge in trading activity Friday due to the company’s recent announcement that it has regained compliance with Nasdaq’s minimum equity rule.

    What To Know: Venus Concept saw its stock price soar by 126.7% in pre-market trading on Friday on continued momentum after the announcement on Thursday. This compliance, achieved after a significant debt-to-equity transaction, has fueled investor confidence and propelled the stock upward.

    Related Link: Venus Concept Stock Soars 127% Premarket After Regaining Nasdaq Compliance

    The company confirmed on June 4 that it had satisfied the stockholders’ equity requirement, after receiving a deficiency notice on May 31, 2023. To meet this requirement, Venus Concept completed a $35 million debt-to-equity transaction on May 28.

    What Else: In addition to this financial restructuring, Venus Concept received a medical device license from Health Canada for its Venus Versa Pro system, allowing the company to market this aesthetic platform in Canada. The Venus Versa Pro system integrates multiple technologies for skin rejuvenation, further bolstering the company’s market position.

    Vero Price Action: Venus Concept shares were up by 85.4% at $1.08 at the time of writing, according to Benzinga Pro.

    See Also: Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

    Image: Courtesy of Venus Concept Inc.

    Get the next $VERO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    SEC Filings

    View All

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Venus Concept Announces Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device ("EBD") revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter. Primarily driven by a decline in the Hair Restoration business (the "Venus Hair Business") impacted by a delay in the pending sale. Third

    11/13/25 7:00:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments

    TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market the Venus NOVA™, the Company's next-generation multi-application platform designed to redefine non-invasive treatments for the body, face, and skin. Venus NOVA integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology -delivering a powerful, comprehensive solution for body contouring, muscle co

    11/10/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP ("Madryn") for 545,335 shares of its Series Y preferred stock. Following the transaction, the Company had total debt obligations of approximately $30.1 million, a reduction of 24% compared to $39.7 million outstanding as of December 31, 2024. "Madryn's invaluable partnership has provided us with financial flexibility as we work towards sustained long

    10/2/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    10/2/25 7:23:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    7/2/25 7:27:23 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    4/2/25 5:47:31 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Financials

    Live finance-specific insights

    View All

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13754867. A live webcast of the call will also be provided on the investor relations section of the Company's

    7/16/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

    4/7/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    View All

    Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

    TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

    10/12/23 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

    TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

    10/11/22 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/8/24 7:51:38 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/3/24 7:59:41 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

    SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

    9/30/24 9:53:26 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care